

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5982475

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
MARCEL MAIER	01/24/2017
JAN GRIMM	01/20/2017
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	NEURIMMUNE HOLDING AG
<b>Street Address:</b>	WAGISTRASSE 13
<b>City:</b>	SCHLIEREN
<b>State/Country:</b>	SWITZERLAND
<b>Postal Code:</b>	8952
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	16784645
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(617)428-7045
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	(617) 428-0200
<b>Email:</b>	patentadmin@clarkelbing.com
<b>Correspondent Name:</b>	CLARK & ELBING LLP
<b>Address Line 1:</b>	101 FEDERAL STREET
<b>Address Line 2:</b>	15TH FLOOR
<b>Address Line 4:</b>	BOSTON, MASSACHUSETTS 02110
<b>ATTORNEY DOCKET NUMBER:</b>	51467-006002
<b>NAME OF SUBMITTER:</b>	SUSAN M. MICHAUD, PH.D.
<b>SIGNATURE:</b>	/Susan M. Michaud, Ph.D./
<b>DATE SIGNED:</b>	02/26/2020
<b>Total Attachments: 2</b>	
source=Executed Assignment#page1.tif	
source=Executed Assignment#page2.tif	

# ASSIGNMENT

For valuable consideration, we,

Full Name of Assignor	City	State (and Country if not USA)
Marcel Maier	Zurich	Switzerland
Jan Grimm	Dübendorf	Switzerland


hereby assign to

Full Name of Assignee	State of Incorporation	Business Address
Neurimmune Holding AG	Switzerland	Wagistrasse 13 8952 Schlieren Switzerland

and to its successors and assigns (collectively hereinafter called "the Assignee"), the entire right, title, and interest throughout the world in the inventions and improvements which are subject of one or more applications for United States Patent signed by us, identified as:

Title of Application	Filing Date	Serial Number
HUMAN-DERIVED ANTI-HUNTINGTIN (HTT) ANTIBODIES AND USES THEREOF	January 4, 2017	15/323,784

and we authorize and request the attorneys appointed in said application to hereafter complete this assignment by inserting above the filing date and serial number of said application when known; this assignment includes said application, any and all United States and foreign patents, utility models, and design registrations granted for any of said inventions or improvements, and the right to claim priority based on the filing date of said application under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; and we authorize the Assignee to apply in all countries in our names or in its own name for patents, utility models, design registrations, and like rights of exclusion, and for inventors' certificates for said inventions and improvements; and we agree for ourselves and our respective heirs, legal representatives and assigns, without further compensation, to perform such lawful acts and to sign such further applications, assignments, Preliminary Statements, and other lawful documents as the Assignee may reasonably request to effectuate fully this assignment. This assignment also includes the right to sue for past acts of infringement, whether based on any patents listed herein, patents issuing from applications listed herein, or provisional rights from any patent applications listed herein.



Marcel Maler


Jan 24, 2017  
Date

Witness:

  
Signature


Jan 24, 2017  
Date

Christine Frei  
Printed name

  
Jan Grimm

JAN 20, 2017  
Date

Witness:

  
Signature


Jan 20, 2017  
Date

Christine Frei  
Printed name

  
Print Name: Michael Salpmann Jan Grimm  
Print Title: CEO CSO  
Neurimmune Holding AG

Jan 20, 2017  
Date

Witness:

  
Signature

Jan 20, 2017  
Date

Christine Frei  
Printed name